Dark

MOLN
Molecular Partners AG
stock NASDAQ ADR

At Close

Sep 15, 2025

3.75USD+0.672%(+0.03)1,003

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-3.72)0

After-hours

Sep 11, 2025 4:00:30 PM EDT

3.63USD0.000%(+3.63)100

Overview HistoricalExchangesShortsNews

Jan 20, 2022

07:40AM EST The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET). RTTNews

Jan 18, 2022

04:25AM EST Molecular Partners Finalized License Agreement with Novartis for Ensovibep for COVID-19; Molecular Partners to Receive Milestone Payment of CHF150M, 22% Royalty on Ensovibep Sales in Relevant Territories Benzinga

01:26AM EST Molecular Partners AG (MOLN), a clinical-stage biotech company developing DARPin therapeutics, Tuesday said it has entered into a license agreement with Novartis AG (NVS), under which the Swiss drug major will in-license global rights to ensovibep from Molecular Partners. RTTNews

01:12AM EST Molecular Partners Finalizes License Deal With Novartis For Ensovibep For COVID-19 RTTNews

01:00AM EST Molecular Partners Finalizes License Agreement with Novartis for GlobeNewswire Inc

Jan 16, 2022

04:38PM EST The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week Benzinga

Jan 14, 2022

12:30PM EST Mid-Day Market Update: Crude Oil Rises Over 1%; FTC Solar Shares Slide Benzinga

08:07AM EST The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake Benzinga

06:09AM EST SVB Leerink Maintains Outperform on Molecular Partners, Raises Price Target to $42 Benzinga

Jan 13, 2022

05:05PM EST Molecular Partners Reports Changes In Ownership: Essex Woodlands Health Ventures Fund Crossed Below 3% Threshold, BVF Partners Crossed Above 10% Threshold To 12.21% Benzinga

05:00PM EST Molecular Partners Reports Disclosure of Major Shareholder as per GlobeNewswire Inc

Jan 11, 2022

10:51AM EST Shares of Molecular Partners AG (MOLN) are currently gaining over 13% on Tuesday morning. On Monday, Novartis said it would license antiviral Covid-19 treatment ensovibep from Molecular Partners after positive trial results. RTTNews

Jan 10, 2022

12:26PM EST Mid-Day Market Update: Nasdaq Dips 300 Points; Apria Shares Surge Benzinga

04:49AM EST Molecular Partners and Novartis Report Topline Data from Phase 2 Study for Ensovibep Show DARPin Antiviral Therapeutic Candidate for COVID-19 vs. Placebo Met Primary Endpoint of Viral Load Reduction over Eight Days Benzinga

02:44AM EST Molecular Partners AG (MOLN) and Novartis announced positive data from phase 2 study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19. RTTNews

01:43AM EST Molecular Partners, Novartis Report Positive Topline Data From Phase 2 Study For Ensovibep RTTNews

01:17AM EST -- Topline results from the randomized, placebo-controlled EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous dosesof ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpointof viral load reduction over eight days GlobeNewswire Inc

Jan 5, 2022

04:05PM EST Molecular Partners AG(SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known asDARPintherapeutics,today announcedthat its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in several upcoming healthcare investor events in January, 2022. GlobeNewswire Inc

Dec 15, 2021

01:00AM EST Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Senior Management and invited guests will host a virtual Oncology R&D Day. GlobeNewswire Inc

Dec 14, 2021

08:22AM EST The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks Benzinga

02:03AM EST Molecular Partners AG (MOLN), a company focused on a new class of custom-built protein drugs- DARPin therapeutics, said on Tuesday that it has entered into a license agreement with Novartis AG (NVS), to make and sell DARPin-conjugated radioligand therapies or DARPin-RLTs. RTTNews

01:08AM EST Molecular Partners Collaborates With Novartis To Develop DARPin Platform With Novartis' In Radioligand Therapy RTTNews

01:00AM EST -- Collaboration to leverage world class capabilities of Molecular Partners DARPin platform with Novartis in radioligand therapy to explore the potential for novel targeted therapies for cancer -- Novartis will pay $20 million upfront, commercial royalties up to low double-digits, and milestone payments. GlobeNewswire Inc

Dec 13, 2021

12:49PM EST Molecular Partners Late Sunday Confirmed Ensovibep Retains Neutralization Of Omicron Variant Of SARS-CoV-2 In Preclinical Studies Benzinga

Dec 12, 2021

04:00PM EST Molecular Partners Confirms Ensovibep Retains Neutralization of GlobeNewswire Inc

Dec 9, 2021

01:00AM EST -- Program overview and study design for MP0317 to be presented at ESMO Immuno-Oncology -- Preclinical data supporting novel mechanism of AML candidate MP0533 to be presented at ASH -- Oncology R&D Day to review cancer therapeutic portfolio and strategy on December 15, 2021 GlobeNewswire Inc

Dec 6, 2021

07:35AM EST Molecular Partners' Ensovibep Shows Early Safety Profile In COVID-19 Benzinga

01:50AM EST Molecular Partners AG (MOLN) presented results from the Phase 2a study of ensovibep for COVID-19 patients, showing that the candidate was safe and well-tolerated. Viral load data showed a comparable decline for both 225 mg and 600 mg dose levels. RTTNews

01:00AM EST Molecular Partners Presents Results from a Phase 2a Trial of GlobeNewswire Inc

Dec 3, 2021

01:00AM EST Molecular Partners Announces Research Collaboration with GlobeNewswire Inc

Nov 30, 2021

04:47PM EST The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout Benzinga

01:00AM EST -- Ensovibep retains activity with regard to all relevant individual positions mutated in Omicron, the newly discovered viral variant of concern -- Testing on the full Omicron variant has initiated, with results expected in the coming weeks -- Global Phase 2-3 EMPATHY clinical study ongoing with topline phase 2 data available in early 2022 GlobeNewswire Inc

Nov 24, 2021

01:00AM EST Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Nov 30, 2021, at 8:00 AM EST. GlobeNewswire Inc

Nov 16, 2021

02:36PM EST Mid-Afternoon Market Update: Dow Jumps 150 Points; Talkspace Shares Slide Benzinga

12:07PM EST Mid-Day Market Update: Crude Oil Down 1%; Kezar Life Sciences Shares Surge Benzinga

10:21AM EST Mid-Morning Market Update: Markets Open Higher; Walmart Tops Q3 Expectations Benzinga

08:31AM EST The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment Benzinga

04:59AM EST Molecular Partners Annoucnced ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19 Did Not Pass Futility Criteria; Share Price Down 37% Premarket Benzinga

01:00AM EST -- Following the futility analysis, the independent Data and Safety Monitoring Board (DSMB) recommends that the recruitment of patients in the ensovibep arm of ACTIV-3 not continue in hospitalized patients -- The global phase 2-3 EMPATHY study in non-hospitalized patients is still ongoing with topline data from phase 2b expected in early 2022 GlobeNewswire Inc

Nov 4, 2021

02:00AM EDT -- Second immuno-oncology DARPin candidate to enter the clinic; combines immune stimulation with validated tumor-localizing technology -- Preclinical data support potential to deliver tumor-localized immune activation while avoiding systemic toxicity seen with other CD40-targeting agents GlobeNewswire Inc

Oct 28, 2021

01:00AM EDT Interim Management Statement Q3 2021 of Molecular Partners: GlobeNewswire Inc

Oct 20, 2021

08:16AM EDT The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review Benzinga

01:00AM EDT -- Ensovibep is shown in vitro to maintain inhibition against all variants of concern known to date -- The Company is also presenting a Trial in Progress poster on the EMPATHY clinical trial at the conference GlobeNewswire Inc

Sep 3, 2021

04:05PM EDT Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at two upcoming virtual healthcare investor events in September 2021. GlobeNewswire Inc

Aug 27, 2021

06:20AM EDT SVB Leerink Maintains Outperform on Molecular Partners, Lowers Price Target to $35 Benzinga

Aug 26, 2021

04:02AM EDT Earnings Scheduled For August 26, 2021 Benzinga

01:00AM EDT -- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3 GlobeNewswire Inc

Aug 9, 2021

07:07AM EDT AbbVie Returns Eye Drug Candidate To Molecular Partners Benzinga

01:00AM EDT -- Global rights to registrational-stage ophthalmology drug return to Molecular Partners -- Improvements in manufacturing and formulation have been made and tested inpre-clinical models with the potential to overcome inflammatory side effects -- Ongoing research discovery alliance with AbbVie in ophthalmology to continue GlobeNewswire Inc

Jul 13, 2021

10:13AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021 Benzinga

06:56AM EDT Cowen Initiates Coverage On Molecular Partners With Price Target Of $50 Benzinga

04:36AM EDT Cowen & Co. Initiates Coverage On Molecular Partners with Outperform Rating, Announces Price Target of $50 Benzinga

Jul 8, 2021

09:05AM EDT Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant Benzinga

01:02AM EDT Molecular Partners Reports Continued Progress of Ensovibep Global GlobeNewswire Inc

Jul 2, 2021

07:38AM EDT The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures Benzinga

Jun 29, 2021

08:17AM EDT The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout Benzinga

Jun 21, 2021

06:27AM EDT HC Wainwright & Co. Assumes Molecular Partners at Buy, Announces Price Target of $25 Benzinga

Jun 16, 2021

11:17AM EDT Molecular Partners Shares Open For Trade At $20; IPO Priced $21.25/Share Benzinga

10:22AM EDT Molecular Partners Shares Indicating $20.75 On 231K Shares Benzinga

10:05AM EDT Molecular Partners Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced $21.25/Share Benzinga

.dark-mode .S61tGD{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .S61tGD{ color: #333333; background-color: white; border: 2px solid #333333; }MOLNMolecular Partners AGstock NASDAQ ADR

MOLN
Molecular Partners AG
stock NASDAQ ADR